WALTHAM, MA -- April 18, 2007 -- PerkinElmer, Inc. (NYSE: PKI), a global leader in Health Sciences and Photonics, has developed a highly-sensitive, homogenous (no-wash) AlphaLISA™ assay for analysis of a wide range of biomarkers and other analytes commonly measured in pharmaceutical and biopharmaceutical research and development and pre-clinical studies in drug discovery. The company has also launched an assay development service to facilitate traditional Enzyme-Linked ImmunoSorbent Assay (ELISA) conversion to this new enabling technology. This service is the first of several planned in a comprehensive approach to assay development for key drug discovery targets.

AlphaLISA assays are especially designed for custom applications requiring the detection of low abundance or proprietary biomarkers and biological therapeutics for which no commercial assay kits are available or are incompatible with complex samples such as serum or plasma. The AlphaLISA technology also offers pharmaceutical laboratories an automated solution for screening common analytes in a high-throughput format.

“Classical ELISA assays have always required many cumbersome wash-steps which not only take more time and effort on the part of the lab personnel, but the washing can also interfere in the analyte detection and introduce variability into the results,” said Richard Eglen, vice president and general manager of the Discovery and Research Reagents business of PerkinElmer Life and Analytical Sciences. “By offering a homogenous alternative to ELISA, labs can easily automate these assays for greater productivity and throughput while achieving higher sensitivity and therefore more accurate, relevant data.”

For laboratories interested in upgrading to this new assay technology, the PerkinElmer scientific team offers a flexible, customized assay development service to facilitate a virtually seamless conversion. Following a consultation with the laboratory, PerkinElmer assay development typically takes two to four weeks. Subsequently training, assay transfer and validation at the customer site are supported by expert scientists.

For more information on AlphaLISA or PerkinElmer’s AlphaLISA Biomarker Assay Development Service, visit PerkinElmer online at: www.perkinelmer.com or contact a PerkinElmer sales representative.

Factors Affecting Future Performance
This press release contains “forward-looking” statements within the meaning of the Private Securities Litigation Reform Act of 1995, including, but not limited to, statements relating to estimates and projections of future earnings per share and revenue growth and other financial results, developments relating to our customers and end-markets, and plans concerning business development opportunities. Words such as “believes,” “intends,” “anticipates,” “plans,” “expects,” “projects,” “forecasts,” “will” and similar expressions, and references to guidance, are intended to identify forward-looking statements. Such statements are based on management’s current assumptions and expectations and no assurances can be given that our assumptions or expectations will prove to be correct. A number of important risk factors could cause actual results to differ materially from the results described, implied or projected in any forward-looking statements. These factors include, without limitation: (1) our failure to introduce new products in a timely manner; (2) our ability to execute acquisitions and license technologies, or to successfully integrate acquired businesses and licensed technologies into our existing business or to make them profitable; (3) our failure to protect adequately our intellectual property; (4) the loss of any of our licenses or licensed rights; (5) our ability to compete effectively; (6) fluctuation in our quarterly operating results and our ability to adjust our operations to address unexpected changes; (7) our ability to produce an adequate quantity of products to meet our customers’ demands; (8) our failure to maintain compliance with applicable government regulations; (9) regulatory changes; (10) economic, political and other risks associated with foreign operations; (11) our ability to retain key personnel; (12) restrictions in our credit agreement; (13) our ability to realize the full value of our intangible assets; and (14) other factors which we describe under the caption “Risk Factors” in our most recent annual report on Form 10-K and in our most recent quarterly report on Form 10-Q and in our other filings with the Securities and Exchange Commission. We disclaim any intention or obligation to update any forward-looking statements as a result of developments occurring after the date of this press release.

Other Information
Health Sciences end markets include genetic screening, environmental, service, biopharma, and medical imaging. Photonics markets include sensors and specialty lighting.